Eptakog alpha

When ATH:
B02BD08

Pharmacological action

Recombinant coagulation factor VIIa. At therapeutic doses associated with a large number of tissue factor, forming a complex, amplifying starting the activation of factor X. In the presence of calcium ions and anionic phospholipids can activate factor X on the surface of activated platelets, acting "bypass" system of the coagulation cascade.

Valid only at the site of damage, and does not cause activation of clotting process Sustem.

Pharmacokinetics

The data is not provided.

Testimony

Bleeding and prevention of massive bleeding during surgery in patients with inherited or acquired haemophilia with inhibitors to coagulation factors VIII and IX coagulation factors; a hereditary deficiency of factor VII.

Dosage regimen

Enter the I / O for 2-5 min bolus injection.

A single dose of 3-6 KED (60-120 g)/kg. The recommended starting dose – 4.5 KED (90 g)/kg. The frequency of administration is determined individually.

Side effect

Rarely: chills, headache, nausea, vomiting, weakness, increased perspiration, changes in blood pressure, redness and itching, renal failure, ataxia, abnormal liver function, cerebrovascular accidents, angina, supraventricular tachycardia, tromboflebit, pulmonary embolism, DIC.

Contraindications

Increased sensitivity to proteins mice, hamsters and cows.

Pregnancy and lactation

When pregnancy is used only in cases of extreme necessity.

Unknown, whether the active substance is released in breast milk. In lactating used with caution.

Cautions

Avoid the simultaneous use of prothrombin complex concentrates.

Drug Interactions

Data on the risk of possible interactions between the drug Eptakog alpha and concentrates of clotting factors are missing. It should not be administered simultaneously prothrombin complex concentrate (activated or not activated) and alpha Eptakog.

According to reports Antifibrinolytics reduce intraoperative blood loss in patients with hemophilia, especially in orthopedic surgery and surgery tissues with high fibrinolytic activity, eg, oral. The experience of the combined use of the drug and antifibrinolytics Eptakog limited alpha.

Eptakog alpha can not be mixed with infusion solutions or nominate a drip.